Definium Therapeutics (NASDAQ:DFTX) Stock Picked Up by Analysts at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a research report issued to clients and investors on Friday, Briefing.com reports. The brokerage set an “overweight” rating and a $84.00 price target on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 145.76% from the stock’s previous close.

Several other analysts have also weighed in on DFTX. Stifel Nicolaus lifted their price objective on Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. JonesTrading raised their target price on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Piper Sandler reiterated an “overweight” rating and set a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Wall Street Zen lowered shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Definium Therapeutics in a research note on Monday, September 14th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Definium Therapeutics has a consensus rating of “Buy” and a consensus target price of $66.00.

Definium Therapeutics Stock Down 2.6%

Shares of DFTX opened at $34.18 on Friday. The company has a 50-day simple moving average of $40.43 and a 200-day simple moving average of $32.95. The firm has a market capitalization of $4.59 billion, a P/E ratio of -9.96 and a beta of 2.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics has a 52 week low of $10.46 and a 52 week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, equities research analysts expect that Definium Therapeutics will post -3.02 earnings per share for the current year.

Insider Activity

In related news, insider Mark Sullivan sold 14,051 shares of Definium Therapeutics stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $513,845.07. Following the completion of the transaction, the insider directly owned 494,228 shares of the company’s stock, valued at $18,073,917.96. This trade represents a 2.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the business’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the completion of the transaction, the chief executive officer owned 2,213,090 shares in the company, valued at approximately $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 71,098 shares of company stock worth $2,626,115. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC acquired a new stake in Definium Therapeutics during the 4th quarter valued at $66,950,000. Wellington Management Group LLP bought a new stake in shares of Definium Therapeutics during the second quarter worth $138,755,000. Bank of New York Mellon Corp grew its holdings in shares of Definium Therapeutics by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after purchasing an additional 24,349 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Definium Therapeutics in the second quarter valued at $6,992,000. Finally, Platinum Investment Management Ltd. acquired a new stake in shares of Definium Therapeutics in the fourth quarter valued at $937,000. 27.91% of the stock is owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.